VMViktoriya A. Mumyatova

Viktoriya A. Mumyatova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Viktoriya A. Mumyatova has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Enhancement of doxorubicin cytotoxic activity by new N-hydroxybutanamide derivatives

    by Viktoriya Mumyatova, Karina Kolesova, Natalya Filatova, Bogdan Tretyakov, Svyatoslav Gadomsky

    The study examined the cytotoxic properties of novel N-hydroxybutanamide derivatives belonging to the hydroxamic acid class. The HDAC-inhibitory activity of these compounds was investigated in vitro, as well as their effects on the cytotoxic properties of the chemotherapeutic agent doxorubicin in tumor cell lines of various origins. The tested compounds exhibited low cytotoxicity and inhibited HDAC activity. The novel derivatives most effectively inhibited histone deacetylase 3 (HDAC3) activity, leading to intracellular hyperacetylation of histone H3 in HeLa cells. These N-hydroxybutanamide-based agents exhibited chemosensitizing properties and enhanced the cytotoxic effect of doxorubicin in HeLa tumor cell lines.

  • The Impact of p53 Knockdown on the Expression of Antioxidant System Genes in Response to Platinum Complexes in Tumor and Non-Tumor Cells

    by V. A. Mumyatova, E. O. Zyrianskii, V. D. Sen’, A. A. Terentiev

    Objective: Oxidative stress and antioxidant defense play crucial roles in carcinogenesis and anticancer therapy. The transcription factor p53, a central regulator of the cellular stress response, is involved in maintaining redox homeostasis; however, its role in regulating the antioxidant system (AOS) under genotoxic stress remains insufficiently studied. In this study, we investigated the influence of p53 on the expression of key AOS genes in both tumor and non-tumor cell lines. p53 induction was modeled by creating stress conditions that trigger the natural cellular response to damaging effects of platinum complexes. Methods: Stable clones with p53 gene knockdown were generated via RNA interference, allowing us to assess the role of p53 in regulating the AOS genes under study. Results: The results demonstrate that platinum complexes upregulate expression of the superoxide dismutase gene (SOD2) in a p53-dependent manner. Under the same conditions, p53 knockdown reduced SOD2 expression back to baseline levels, indicating that p53 is required for SOD2 induction during genotoxic stress. In contrast, catalase (CAT) gene expression varied depending on cell type and the nature of the stress stimulus. Conclusions: These findings highlight the critical role of p53 in modulating the antioxidant response under genotoxic stress and provide new insights into its functions in oxidative homeostasis and cancer therapy.

  • Open Access

    Combining Experimental and Computational Methods to Produce Conjugates of Anticholinesterase and Antioxidant Pharmacophores with Linker Chemistries Affecting Biological Activities Related to Treatment of Alzheimer’s Disease

    by Galina F. Makhaeva, Nadezhda V. Kovaleva, Elena V. Rudakova, Natalia P. Boltneva, Sofya V. Lushchekina, Tatiana Y. Astakhova, Elena N. Timokhina, Igor V. Serkov, Alexey N. Proshin, Yuliya V. Soldatova, et al.

    Effective therapeutics for Alzheimer’s disease (AD) are in great demand worldwide. In our previous work, we responded to this need by synthesizing novel drug candidates consisting of 4-amino-2,3-polymethylenequinolines conjugated with butylated hydroxytoluene via fixed-length alkylimine or alkylamine linkers (spacers) and studying their bioactivities pertaining to AD treatment. Here, we report significant extensions of these studies, including the use of variable-length spacers and more detailed biological characterizations. Conjugates were potent inhibitors of acetylcholinesterase (AChE, the most active was 17d IC50 15.1 ± 0.2 nM) and butyrylcholinesterase (BChE, the most active was 18d: IC50 5.96 ± 0.58 nM), with weak inhibition of off-target carboxylesterase. Conjugates with alkylamine spacers were more effective cholinesterase inhibitors than alkylimine analogs. Optimal inhibition for AChE was exhibited by cyclohexaquinoline and for BChE by cycloheptaquinoline. Increasing spacer length elevated the potency against both cholinesterases. Structure–activity relationships agreed with docking results. Mixed-type reversible AChE inhibition, dual docking to catalytic and peripheral anionic sites, and propidium iodide displacement suggested the potential of hybrids to block AChE-induced β-amyloid (Aβ) aggregation. Hybrids also exhibited the inhibition of Aβ self-aggregation in the thioflavin test; those with a hexaquinoline ring and C8 spacer were the most active. Conjugates demonstrated high antioxidant activity in ABTS and FRAP assays as well as the inhibition of luminol chemiluminescence and lipid peroxidation in mouse brain homogenates. Quantum-chemical calculations explained antioxidant results. Computed ADMET profiles indicated favorable blood–brain barrier permeability, suggesting the CNS activity potential. Thus, the conjugates could be considered promising multifunctional agents for the potential treatment of AD.


  • Open Access

    Synthesis, Antibacterial Activity, and Cytotoxicity of Azido-Propargyloxy 1,3,5-Triazine Derivatives and Hyperbranched Polymers

    by Anna V. Tsyganova, Artem O. Petrov, Alexey V. Shastin, Natalia V. Filatova, Victoria A. Mumyatova, Alexander E. Tarasov, Alina V. Lolaeva, Georgiy V. Malkov

    A new method for the synthesis of azido-propargyloxy derivatives of 1,3,5-triazine has been developed utilizing the nitrosation of hydrazyno-1,3,5-triazines. New hydrazines (2-hydrazino-4,6-bis(propargyloxy)-1,3,5-triazine and 2,4-dihydrazino-6-propargyloxy-1,3,5-triazine) were synthesized and characterized via FTIR, NMR spectroscopy and elemental analysis. The hyperbranched polymers with azide (diazide monomer) and propargyloxy terminal groups were obtained via the azide-alkyne polycycloaddition reaction of diazide and monoazide AB2-type monomers. The antibacterial activity against Escherichia coli bacteria of 2,4,6-trispropargyloxy-1,3,5-triazine, 2-azido-4,6-bispropargyloxy-1,3,5-triazine, and 2,4-diazido-6-propargyloxy-1,3,5-triazine and their hyperbranched polymers was studied. Only 2,4-diazido-6-propargyloxy-1,3,5-triazine has weak antibacterial activity in comparison with ampicillin. The cytotoxicity of these compounds against M-HeLa, FetMSC, and Vero cell lines was also studied. 2,4,6-trispropargyloxy-1,3,5-triazine does not show any cytotoxic effect (IC50 ≥ 280 µM). It was shown that the presence of an azide group in the compound directly affects the cytotoxic effect. Hyperbranched polymers have a less cytotoxic effect against M-HeLa (IC50 > 100) in comparison with monomers (IC50 = 90–99 µM). This makes it possible to use these polymers as the basis for biocompatible materials in biomedical applications.


  • Open Access

    Synthesis, Antibacterial Activity and Cytotoxicity of Azido-Propargyloxy 1,3,5-Triazine Derivatives and Hyperbranched Polymers

    by Anna V. Tsyganova, Artem O. Petrov, Aleksey V. Shastin, Natalia V. Filatova, Victoria A. Mumyatova, Alexander E. Tarasov, Georgiy V. Malkov

    A new method for the synthesis of azido-propargyloxy derivatives of 1,3,5-triazine has been developed. The antibacterial activity against E. coli bacteria of propargyloxy substituted 1,3,5-triazines - 2,4,6-trispropargyloxy-1,3,5-triazine, 2-azido-4,6-bispropargyloxy-1,3,5-triazine and 2,4-diazido-6-propargyloxy-1,3,5-triazine and their hyperbranched polymers. It has been shown that the presence of an azide group in the compound directly affects the antibacterial activity. The cytotoxicity of these compounds against the M-HeLa, FetMSC and Vero cell lines was studied. The IC50 value was determined for low molecular weight compounds. It has been shown that hyperbranched polymers without azide groups don’t exhibit pronounced cytotoxicity and can be used in biomedical applications.

  • Open Access

    Combining Experimental and Computational Methods to Produce Conjugates of Anticholinesterase and Antioxidant Pharmacophores with Linker Chemistries Affecting Biological Activities Related to Treatment of Alzheimer's Disease

    by Galina F. Makhaeva, Nadezhda V. Kovaleva, Еlena V. Rudakova, Natalia P. Boltneva, Sofya V. Lushchekina, Tatiana Y. Astakhova, Elena N. Timokhina, Igor V. Serkov, Alexey N. Proshin, Yuliya V. Soldatova, et al.

    Effective therapeutics for Alzheimer's disease (AD) are in great demand worldwide. In our previous work, we responded to this need by synthesizing novel drug candidates consisting of 4-amino-2,3-polymethylenequinolines conjugated with butylated hydroxytoluene via fixed-length alkylimine or alkylamine linkers (spacers) and studying their bioactivities pertaining to AD treatment. Here, we report significant extensions of these studies, including the use of variable-length spacers and more detailed biological characterizations. Conjugates were potent inhibitors of acetylcholinesterase (AChE, minimum IC50 15.1±0.2 nM) and butyrylcholinesterase (BChE, minimum IC50 5.96±0.58 nM), with weak inhibition of off-target carboxylesterase. Conjugates with alkylamine spacers were more effective cholinesterase inhibitors than alkylimine analogs. Optimal inhibition for AChE was exhibited by cyclohexaquinoline and for BChE by cycloheptaquinoline. Increasing spacer length elevated potency against both cholinesterases. Structure-activity relationships agreed with docking results. Mixed-type reversible AChE inhibition, dual docking to catalytic and peripheral anionic sites, and propidium iodide displacement suggested the potential of hybrids to block AChE-induced β-amyloid (Aβ) aggregation. Hybrids also exhibited inhibition of Aβ self-aggregation in the thioflavin test; those with a hexaquinoline ring and C8 spacer were the most active. Conjugates demonstrated high antioxidant activity in ABTS and FRAP assays as well as inhibition of luminol chemiluminescence and lipid peroxidation in mouse brain homogenates. Quantum-chemical calculations explained antioxidant results. Computed ADMET profiles indicated favorable blood-brain barrier permeability suggesting CNS activity potential. Thus, the conjugates could be considered promising multifunctional agents for potential treatment of AD.